Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3008
Name invasive ductal carcinoma
Definition A breast ductal carcinoma that is characterized by infiltration into the fibrous or fatty tissue of the breast outside of the duct where it originated.
Source DiseaseOntology.org
Alt Ids DOID:3005
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast ductal carcinoma invasive ductal carcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 V564L Pemigatinib invasive ductal carcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02779855 Phase Ib/II Paclitaxel + Talimogene laherparepvec Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03356860 Phase Ib/II Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) Completed BEL 0
NCT03596073 Phase I Calcipotriene Topical Calcipotriene Treatment for Breast Cancer Immunoprevention Recruiting USA 0
NCT03725059 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 16
NCT04129216 Phase II Letrozole Tamoxifen Exemestane The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer Active, not recruiting USA 0
NCT04781725 Phase II INT230-6 Intratumoral INT230-6 in Breast Cancer Unknown status CAN 0